DOCSLIB.ORG

National Master List of Drugs and Lab Reagents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

PHASE VIII Annex 01- National Master List of Drugs &Lab Reagents * Important Note:All human products must be of human recombinant origin wherever these are available in the market *For oral solution it is preferable:Syrup then Suspension and then Elixir MOH CODE ITEM NAME 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1Aa Digtalis glycoside 02-01-00001 digoxin tab 62.5 mcg 650000 02-01-00002 digitoxin tab 100 mcg 650000 02-01-00003 digoxin tab 125 mcg 650000 02-01-00004 digoxin tab 250 mcg 33000000 02-01-00005 digoxin PG elixir 50mcg /ml 650000 02-01-00006 digoxin inj 250 mcg/ml, (2ml amp) 650000 1Ab PHOSPHODIESTERASE INHIBITORS 02-01-00007 Enoximone inj 5mg/ml (20ml amp) 650000 1B DIURETICS 02-01-00008 amiloride Hcl 5mg + hydrochlorthiazide 50mg tab 40000000 02-01-00009 bumetanide tab 1 mg 1000000 02-01-00010 chlorthalidone tab 50mg 3000000 02-01-00011 ethacrynic acid as sod.salt inj powder for reconstitution 50mg vial 650000 02-01-00012 frusemide inj 20mg/2ml amp 7312500 02-01-00013 frusemide I.V. infusion inj 10mg/ml, (25ml amp) 650000 02-01-00014 frusemide tab 40mg 25000000 02-01-00015 frusemide scored tab 500mg 650000 02-01-00016 frusemide oral solution pead liquid 1mg/1ml 650000 02-01-00017 frusemide oral solution 4mg/ml 650000 02-01-00018 frusemide oral solution 8mg/ml 650000 02-01-00019 hydrochlorothiazide tab 25mg 2597400 02-01-00020 hydrochlorothiazide tab 50mg 3482700 02-01-00021 indapamide tab 2.5mg 650000 02-01-00022 Indapamide 1.5mg s/r coated tab 650000 02-01-00023 spironolactone tab 25mg 7282000 02-01-00024 spironolactone tab 100mg 6774000 02-01-00025 Xipamide tab 20mg 650000 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00026 acebutolol tab 100mg 650000 02-01-00027 acebutolol tab 200mg 650000 02-01-00028 atenolol tab 100mg 90000000 02-01-00029 atenolol tab or (scored tab) 50mg 20000000 02-01-00030 atenolol tab 25mg 1000000 02-01-00031 Bisoprolol fumarate scored tab 5mg 650000 02-01-00032 Bisoprolol fumarate scored tab 10mg 650000 02-01-00033 Carvedilol 6.25mg tab 650000 02-01-00034 Carvedilol 12.5mg tab 650000 02-01-00035 Carvedilol 25mg tab 650000 02-01-00036 Esmolol Hcl IV infusion 10mg/ml (10ml vial) 650000 02-01-00037 labetalol inj 5mg/ml (20ml amp) 650000 02-01-00038 labetalol tab 200mg 650000 02-01-00039 labetalol tab 400mg 650000 02-01-00040 metoprolol tab 50mg 650000 02-01-00041 metoprolol tab (s/r) 200mg 650000 02-01-00042 metoprolol tartrate I.V. inj 1mg/1ml (5ml amp) 650000 02-01-00043 nadolol tab 80mg 650000 02-01-00044 oxprenolol Hcl tab 40mg 1376700 02-01-00045 pindolol tab 5mg 1100000 02-01-00046 propranolol Hcl slow IV inj 1mg/ml (1ml amp) 650000 02-01-00047 propranolol Hcl tab 10mg 30000000 02-01-00048 propranolol Hcl tab (or scored tab) 40mg 50000000 02-01-00049 propranolol Hcl cap (s/r) 80mg 700000 1 121 PHASE VIII Annex 01- National Master List of Drugs &Lab Reagents * Important Note:All human products must be of human recombinant origin wherever these are available in the market *For oral solution it is preferable:Syrup then Suspension and then Elixir MOH CODE ITEM NAME 02-01-00050 sotalol tab 40mg 650000 02-01-00051 sotalol tab 80mg 650000 1D ANTI-ARRHYTHMIC DRUGS 02-01-00052 amiodarone Hcl inj 50mg/ml (3ml amp) 650000 02-01-00053 Amiodarone Hcl tab 200mg 7500000 02-01-00054 bretylium tosylate inj 50mg/ml,( 10ml amp) 650000 02-01-00055 disopyramide caps 100mg 2000000 02-01-00056 disopyramide tab (s/r) durules 150mg 650000 02-01-00057 disopyramide tab retard (s/r) 250mg 650000 02-01-00058 disopyramide inj 10mg/ml, (5ml amp) 650000 02-01-00059 lignocaine Hcl I.V. slow infusion inj 20mg/ml, (50ml vial) plain 650000 02-01-00060 lignocaine Hcl inj 50mg/ml, (2ml amp) Spinal 650000 02-01-00061 mexiletine Hcl caps 50mg 650000 02-01-00062 mexiletine Hcl caps 200mg 2300000 02-01-00063 mexiletine Hcl IV,IV infusion inj 25mg/ml, (10ml amp) 650000 02-01-00064 phenytoin sod.inj 50mg/ml, (5ml amp) 650000 02-01-00065 practolol inj 2mg/ml, (5ml amp) 650000 02-01-00066 procainamide Hcl slow I.V.I.V infusion inj 100mg/ml, (10ml vial) 650000 02-01-00067 procainamide Hcl tab 500mg 650000 02-01-00068 procainamide Hcl tab (s/r) 750mg 650000 02-01-00069 propafenon Hcl tab 150mg 650000 02-01-00070 quinidine Bisulfate tab (s/r) 250mg (Durules) 650000 02-01-00071 quinidine Sulphate tab 200mg 650000 02-01-00072 verapamil Hcl inj 2.5mg/ml, (2ml amp) 650000 02-01-00073 verapamil Hcl tab 40mg 4500000 02-01-00074 verapamil Hcl tab 80mg 1200000 02-01-00075 verapamil Hcl tab (s/r) 120mg or cap, 650000 1E ANTI-HYPERTENSIVE DRUGS 02-01-00076 alfuzosin Hcl tab 2.5mg 860000 02-01-00077 alfuzosin Hcl (S/R) tab 5mg 1100000 02-01-00078 captopril tab 25mg 70000000 02-01-00079 captopril tab 50mg 45000000 02-01-00080 Candesartan cilexetil scored tab 8mg 650000 02-01-00081 diazoxide tab 50mg 650000 02-01-00082 doxazosin scored tab 2mg 1227000 02-01-00083 enalapril maleate scored tab 5mg 650000 02-01-00084 enalapril maleate scored tab 10mg 1425000 02-01-00085 enalapril maleate scored tab 20mg 1006200 02-01-00086 hydralazine Hcl I.V. infusion inj 20mg per amp 650000 02-01-00087 hydralazine Hcl tab 25mg 650000 02-01-00088 hydralazine Hcl tab 50mg 650000 02-01-00089 Lisinopril tab 5mg 650000 02-01-00090 Lisinopril tab 10mg 1142000 02-01-00091 Lisinopril tab 20mg 706000 02-01-00092 Losartan potassium tab 50mg 650000 02-01-00093 methyldopa inj 50mg/ml, (5ml amp) 650000 02-01-00094 methyldopa tab 250mg 68000000 02-01-00095 minoxidil tab 5mg 650000 02-01-00096 minoxidil tab 10mg 650000 02-01-00097 Perindopril Tert-butylamine erbumine 2mg tab 650000 02-01-00098 Perindopril Tert-butylamine erbumine 4mg tab 650000 02-01-00099 phenoxybenzamine Hcl caps 10mg 12000000 02-01-00100 phenoxybenzamine Hcl inj 50mg/ml, (2ml amp) 650000 02-01-00101 phentolamine mesylate inj 10mg/ml, (1ml amp) 650000 02-01-00102 prazosin Hcl tab 0.5mg 650000 2 121 PHASE VIII Annex 01- National Master List of Drugs &Lab Reagents * Important Note:All human products must be of human recombinant origin wherever these are available in the market *For oral solution it is preferable:Syrup then Suspension and then Elixir MOH CODE ITEM NAME 02-01-00103 prazosin Hcl tab or scored tab 1mg 650000 02-01-00104 prazosin Hcl tab 2mg 650000 02-01-00105 prazosin Hcl tab 5mg 650000 02-01-00106 Quinapril Hcl tab 5mg 650000 02-01-00107 Quinapril Hcl tab 10mg 650000 02-01-00108 Quinapril Hcl tab 20mg 650000 02-01-00109 Ramipril scored tab or cap: 2.5mg 650000 02-01-00110 Ramipril scored tab or cap: 5mg 750000 02-01-00111 Ramipril scored tab or cap: 10mg 1350000 02-01-00112 Ramipril cap: 1.25mg 650000 02-01-00113 reserpine tab 100mcg 650000 02-01-00114 sodium nitroprusside I.V.infusion 50mg amp with solvent 650000 02-01-00115 tolazoline Hcl inj i.v 650000 02-01-00116 Valsartan cap 160mg 1674000 02-01-00117 Valsartan cap 40mg 650000 02-01-00118 Valsartan cap 80mg 765000 02-01-00119 Telmisartan 40mg tab 650000 02-01-00120 Telmisartan 80mg tab 650000 1F VASODILATORS 02-01-00121 Amlodipine (as besylate) tab 2.5mg 650000 02-01-00122 Amlodipine (as besylate) scored tab 5mg 650000 02-01-00123 Amlodipine (as besylate) scored tab 10mg 650000 02-01-00124 cinnarizine tab 25mg 25000000 02-01-00125 cinnarizine cap or tab 75mg 4000000 02-01-00126 diltiazem Hcl cap or tab 30mg 650000 02-01-00127 diltiazem Hcl cap or tab 60mg 23000000 02-01-00128 Diltiazem Hcl cap or tab (s/r) or (c/r) 90mg 13000000 02-01-00129 diltiazem Hcl cap or tab (s/r) 120mg 10000000 02-01-00130 diltiazem Hcl IV inj or infusion 25mg/vial 650000 02-01-00131 diltiazem Hcl cap or tab 90mg 1000000 02-01-00132 diltiazem Hcl cap or tab 120mg 1000000 02-01-00133 diltiazem Hcl (s/r) cap or tab 60mg 1200000 02-01-00134 diltiazem Hcl once daily cap or tab 120mg 650000 02-01-00135 diltiazem Hcl once daily cap or tab 180mg 650000 02-01-00136 diltiazem Hcl once daily cap or tab 240mg 650000 02-01-00137 diltiazem Hcl once daily cap or tab 300mg 650000 02-01-00138 Felodipine 5mg tab 650000 02-01-00139 glyceryl trinitrate tab 0. 5mg 60000000 02-01-00140 glyceryl trinitrate inj 5mg/10ml amp. 650000 02-01-00141 glyceryl trinitrate plaster 5mg 650000 02-01-00142 glyceryl trinitrate plaster 10mg 650000 02-01-00143 glyceryl trinitrate plaster 15mg 650000 02-01-00144 glyceryl trinitrate plaster 25mg 650000 02-01-00145 glyceryl trinitrate spray 650000 02-01-00146 glyceryl trinitrate tab (c/r) 2.6mg 650000 02-01-00147 glyceryl trinitrate tab (c/r) 6.4mg 650000 02-01-00148 isosorbide dinitrate tab (s/l) 5mg 15000000 02-01-00149 isosorbide dinitrate tab 10mg 100000000 02-01-00150 isosorbide dinitrate tab (s/r) 20mg 650000 02-01-00151 isosorbide dinitrate tab (s/r) 40mg 650000 02-01-00152 isosorbide mononitrate tab 10mg 650000 02-01-00153 isosorbide mononitrate tab or cap 20mg 650000 02-01-00154 Isosorbide mononitrate 40 mg tab 650000 02-01-00155 Isosorbide mononitrate 60 mg tab 650000 02-01-00156 isosorbide mononitrate tab(s/r)25mg or cap 650000 3 121 PHASE VIII Annex 01- National Master List of Drugs &Lab Reagents * Important Note:All human products must be of human recombinant origin wherever these are available in the market *For oral solution it is preferable:Syrup then Suspension and then Elixir MOH CODE ITEM NAME 02-01-00157 isosorbide mononitrate tab(s/r)50mg or cap 650000 02-01-00158 Nicardipine Hcl IV inj 25mg (solution)/ amp 650000 02-01-00159 nifedipine caps 5mg 650000 02-01-00160 nifedipine caps 10mg 84000000 02-01-00161 nifedipine (s/r) caps or tab 10mg 650000 02-01-00162 nifedipine caps or tab (s/r) 20mg 15000000 02-01-00163 nifedipine caps or tab (s/r) 30mg (24hr) 650000 02-01-00164 nifedipine caps (s/r) 60mg (24hr) 650000 02-01-00165 nimodipine
Recommended publications
  • Amidotrizoic Acid/Barium Sulfate 1477 Imbalance Should Be Corrected Before Contrast Media Are Given

    Amidotrizoic Acid/Barium Sulfate 1477 Imbalance Should Be Corrected Before Contrast Media Are Given

    Amidotrizoic Acid/Barium Sulfate 1477 imbalance should be corrected before contrast media are given. management of adhesive small bowel obstruction;2 they allow pyloric stenosis or lesions that may predispose to obstruction. Particular care is needed in patients with multiple myeloma since identification of patients who require surgery and, although they Adequate hydration should be ensured after the procedure to pre- dehydration resulting from use of contrast media may cause pre- have not been shown to relieve obstruction, they may reduce vent severe constipation. cipitation of protein in the renal tubules, leading to anuria and length of hospital stay in patients treated without surgery. It is contra-indicated in patients with gastrointestinal perforation, fatal renal failure. 1. Murshed R, et al. Meconium ileus: a ten-year review of thirty-six and should be avoided, particularly when given rectally, in those Caution is also necessary in patients with severe hypertension, patients. Eur J Pediatr Surg 1997; 7: 275–7. at risk of perforation, such as patients with acute ulcerative colitis advanced cardiac disease, phaeochromocytoma, sickle-cell dis- 2. Abbas S, et al. Oral water soluble contrast for the management or diverticulitis and after rectal or colonic biopsy, sigmoidosco- of adhesive small bowel obstruction. Available in The Cochrane ease, or hyperthyroidism or epilepsy, and in debilitated, severely Database of Systematic Reviews; Issue 3. Chichester: John Wi- py, or radiotherapy. ill, very old, or very young patients. ley; 2007 (accessed 14/07/08). Uses and Administration Amidotrizoates and other hypertonic contrast media are neuro- Preparations Barium sulfate is used as a radiographic contrast medium toxic and should not be given intrathecally; patients with sub- (p.1474) for X-ray examination of the gastrointestinal tract in- arachnoid haemorrhage may be at risk with any intravascular BP 2008: Meglumine Amidotrizoate Injection; Sodium Amidotrizoate In- jection; volving single- or double-contrast techniques or computed tom- use.
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Adansonia Digitata L

    Adansonia Digitata L

    Veterinary World, EISSN: 2231-0916 RESEARCH ARTICLE Available at www.veterinaryworld.org/Vol.7/July-2014/10.pdf Open Access Antidiarrhoeal effect of the crude methanol extract of the dried fruit of Adansonia digitata L. (Malvaceae) Mohammed Musa Suleiman1111 , Mohammed Mamman , Ibrahim Hassan , Shamsu Garba , Mohammed Umaru Kawu21 and Patricia Ishaku Kobo 1. Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria, Nigeria; 2. Department of Physiology, Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria, Nigeria. Corresponding author: Mohammed Musa Suleiman, email:[email protected] MM: [email protected], IH: [email protected], SG: [email protected], MUK: [email protected], PIK: [email protected] Received:06-04-2014, Revised: 12-06-2014, Accepted: 14-06-2014, Published online: 19-07-2014 doi: 10.14202/vetworld.2014.495-500 How to cite this article: Suleiman MM, Mamman M, Hassan I, Garba S, Kawu MUand Kobo PI (2014) Antidiarrhoeal effect of the crude methanol extract of the dried fruit ofAdansonia digitata L. (Malvaceae), Veterinary World 7(7): 495-500. Abstract Aim: The study was designed to evaluate the antidiarrhoeal property of the methanol extract of the fruit of Adansonia digitata using laboratory animal models. Materials and Methods : The acute oral toxicity (LD50 ) of the extract was determined in mice, while the antidiarrhoeal effect of different doses of the extract was evaluated in both mice and rats. The effect of the extract at doses of 300, 700 and 1000 mg/kg were tested against intestinal transit time, magnesium sulphate-induced gastrointestinal motility test and castor oil- induced diarrhoea in mice.
  • Evidence for the Involvement of Spinal Cord 1 Adrenoceptors in Nitrous

    Evidence for the Involvement of Spinal Cord 1 Adrenoceptors in Nitrous

    Anesthesiology 2002; 97:1458–65 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Evidence for the Involvement of Spinal Cord ␣ 1 Adrenoceptors in Nitrous Oxide–induced Antinociceptive Effects in Fischer Rats Ryo Orii, M.D., D.M.Sc.,* Yoko Ohashi, M.D.,* Tianzhi Guo, M.D.,† Laura E. Nelson, B.A.,‡ Toshikazu Hashimoto, M.D.,* Mervyn Maze, M.B., Ch.B.,§ Masahiko Fujinaga, M.D.ʈ Background: In a previous study, the authors found that ni- opioid peptide release in the brain stem, leading to the trous oxide (N O) exposure induces c-Fos (an immunohisto- 2 activation of the descending noradrenergic inhibitory chemical marker of neuronal activation) in spinal cord ␥-ami- nobutyric acid–mediated (GABAergic) neurons in Fischer rats. neurons, which results in modulation of the pain–noci- 1 In this study, the authors sought evidence for the involvement ceptive processing in the spinal cord. Available evi- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/6/1458/337059/0000542-200212000-00018.pdf by guest on 01 October 2021 ␣ of 1 adrenoceptors in the antinociceptive effect of N2O and in dence suggests that at the level of the spinal cord, there activation of GABAergic neurons in the spinal cord. appear to be at least two neuronal systems that are Methods: Adult male Fischer rats were injected intraperitone- involved (fig. 1). In one of the pathways, activation of ally with ␣ adrenoceptor antagonist, ␣ adrenoceptor antago- 1 2 ␣ nist, opioid receptor antagonist, or serotonin receptor antago- the 2 adrenoceptors produces either direct presynaptic nist and, 15 min later, were exposed to either air (control) or inhibition of neurotransmitter release from primary af- 75% N2O.
  • Norfolk & Waveney Prescriber

    Norfolk & Waveney Prescriber

    The Norfolk & Waveney Prescriber Issue 119 April 2017 For Primary and Secondary Care Health Professionals in Norfolk & Waveney In this issue: Prescribing Safety News: MHRA Drug Safety Updates 2 TAG and Commissioning News 3-4 Drugs – discontinued, shortages and prices 5-6 Drugs – supply issues 7-8 Guidance and Policy News: - National: “NICE Bites” & NICE guidance 9-10 Guidance and Policy News: - Local: Key Message Bulletins 11-12 Cost-effective Prescribing Tips: 13 Ophthalmic Special Order products Atorvastatin Hot Topic: Multimorbidity and Polypharmacy 14 Prescribing Safety: Medicines and Serotonin Syndrome 15-16 Prescribing Advice: Metformin, Finasteride, and Inhalers 17-18 New Medicines & Indications News 19 Feedback and comments on this edition to [email protected] / 01603 257035 Prescribing & Medicines Management Team – 1 NEL CSU Anglia Prescribing Safety News Main points from MHRA Drug Safety Updates February - March 2017 Articles relevant to Primary Care and Secondary Care: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) Canagliflozin may increase the risk of lower-limb amputation (mainly toes) in patients with type 2 diabetes. Evidence does not show an increased risk for dapagliflozin and empagliflozin, but the risk may be a class effect. Preventive foot care is important for all patients with diabetes. Advice for healthcare professionals: o carefully monitor patients receiving canagliflozin who have risk factors for amputation, such as poor control of diabetes and problems with
  • Eosin Y Catalysed Photoredox Synthesis: a Review

    Eosin Y Catalysed Photoredox Synthesis: a Review

    RSC Advances REVIEW View Article Online View Journal | View Issue Eosin Y catalysed photoredox synthesis: a review a b Cite this: RSC Adv.,2017,7,31377 Vishal Srivastava and Praveen P. Singh * In recent years, photoredox catalysis using eosin Y has come to the fore front in organic chemistry as a powerful strategy for the activation of small molecules. In a general sense, these approaches rely on the ability of organic dyes to convert visible light into chemical energy by engaging in single-electron Received 14th May 2017 transfer with organic substrates, thereby generating reactive intermediates. In this perspective, we Accepted 13th June 2017 highlight the unique ability of photoredox catalysis to expedite the development of completely new DOI: 10.1039/c7ra05444k reaction mechanisms, with particular emphasis placed on multicatalytic strategies that enable the rsc.li/rsc-advances construction of challenging carbon–carbon and carbon–heteroatom bonds. 1. Introduction However, the transition metal based photocatalysts disadvantageously exhibit high cost, low sustainability and Visible light photoredox catalysis has recently received much potential toxicity. Recently, a superior alternative to transition Creative Commons Attribution 3.0 Unported Licence. attention in organic synthesis owing to ready availability, metal photoredox catalysts, especially metal-free organic dyes sustainability, non-toxicity and ease of handling of visible particularly eosin Y has been used as economically and 1–13 light but the general interest in the eld started much ecologically superior surrogates for Ru(II)andIr(II)complexes earlier.14 Unlike thermal reactions, photoredox processes occur in visible-light promoted organic transformations involving 18–21 under mild conditions and do not require radical initiators or SET (single electron transfer).
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Ondansetron Does Not Attenuate the Analgesic Efficacy of Nefopam Kai-Zhi Lu 1*, Hong Shen 2*, Yan Chen 1, Min-Guang Li 1, Guo-Pin Tian 1, Jie Chen 1

    Ondansetron Does Not Attenuate the Analgesic Efficacy of Nefopam Kai-Zhi Lu 1*, Hong Shen 2*, Yan Chen 1, Min-Guang Li 1, Guo-Pin Tian 1, Jie Chen 1

    Int. J. Med. Sci. 2013, Vol. 10 1790 Ivyspring International Publisher International Journal of Medical Sciences 2013; 10(12):1790-1794. doi: 10.7150/ijms.5386 Research Paper Ondansetron Does Not Attenuate the Analgesic Efficacy of Nefopam Kai-zhi Lu 1*, Hong Shen 2*, Yan Chen 1, Min-guang Li 1, Guo-pin Tian 1, Jie Chen 1 1. Department of Anaesthesiology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China; 2. Department of Radiology, Chongqing Fifth Hospital, Chongqing.400062, China. * These authors contributed equally to this work. Corresponding author: Dr. Jie Chen: Department of Anaesthesiology, Southwest Hospital, Third Military Medical University, Gaotanyan 19 Street, Shapingba, Chongqing 400038, China. Tel: 0086-23-68754197. Fax: 0086-23-65463285. E-mail: [email protected] © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2012.10.15; Accepted: 2013.10.17; Published: 2013.10.29 Abstract Objectives: The aim of this study was to investigate if there is any interaction between ondansetron and nefopam when they are continuously co-administrated during patient-controlled intravenous analgesia (PCIA). Methods: The study was a prospective, randomized, controlled, non-inferiority clinical trial com- paring nefopam-plus-ondansetron to nefopam alone. A total of 230 postoperative patients using nefopam for PCIA, were randomly assigned either to a group receiving continuous infusion of ondansetron (Group O) or to the other group receiving the same volume of normal saline con- tinuously (Group N).
  • Thermodynamic Quantities for the Ionization Reactions of Buffers

    Thermodynamic Quantities for the Ionization Reactions of Buffers

    Thermodynamic Quantities for the Ionization Reactions of Buffers Robert N. Goldberg,a… Nand Kishore,b… and Rebecca M. Lennen Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899 ͑Received 21 June 2001; accepted 16 September 2001; published 24 April 2002͒ This review contains selected values of thermodynamic quantities for the aqueous ionization reactions of 64 buffers, many of which are used in biological research. Since the aim is to be able to predict values of the ionization constant at temperatures not too far from ambient, the thermodynamic quantities which are tabulated are the pK, standard ⌬ ؠ ⌬ molar Gibbs energy rG , standard molar enthalpy rH°, and standard molar heat ca- ؠ ⌬ pacity change rC p for each of the ionization reactions at the temperature T ϭ298.15 K and the pressure pϭ0.1 MPa. The standard state is the hypothetical ideal solution of unit molality. The chemical name͑s͒ and CAS registry number, structure, empirical formula, and molecular weight are given for each buffer considered herein. The selection of the values of the thermodynamic quantities for each buffer is discussed. © 2002 by the U.S. Secretary of Commerce on behalf of the United States. All rights reserved. Key words: buffers; enthalpy; equilibrium constant; evaluated data; Gibbs free energy; heat capacity; ionization; pK; thermodynamic properties. Contents 7.19. CAPSO.............................. 263 7.20. Carbonate............................ 264 7.21. CHES............................... 264 1. Introduction................................ 232 7.22. Citrate............................... 265 2. Thermodynamic Background.................. 233 7.23. L-Cysteine............................ 268 3. Presentation of Data......................... 234 7.24. Diethanolamine........................ 270 4. Evaluation of Data. ........................ 235 7.25. Diglycolate..........................
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection

    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection

    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
  • In Vivo Evaluation of Antidiarrhoeal Activity of the Leaves of Azima Tetracantha Linn

    In Vivo Evaluation of Antidiarrhoeal Activity of the Leaves of Azima Tetracantha Linn

    Vol.5(8), pp. 140-144, December, 2013 DOI: 10.5897/IJNAM2013.0152 International Journal of Nutrition and ISSN 2141-2340 ©2013 Academic Journals http://www.academicjournals.org/IJNAM Metabolism Full Length Research Paper In vivo evaluation of antidiarrhoeal activity of the leaves of Azima tetracantha Linn V. Hazeena Begum*, M. Dhanalakshmi and P. Muthukumaran Department of Siddha Medicine, Faculty of Science, Tamil University, Vakaiyur, Thanjavur 613 010, Tamilnadu, India. Accepted 3 October, 2013 The aqueous crude extract of the leaves of Azima tetracantha was studied for its phytochemical constituents and antidiarrhoeal activity using castor oil-induced diarrhoea and castor oil-induced enteropooling in rats. The phytochemical studies of the aqueous extract revealed the presence of alkaloids, flavonoids, tannins and saponins. The extract showed significant (p < 0.001) protection against castor oil-induced diarrhoea and castor oil-induced enteropooling at (100 mg/kg). The presence of some of the phytochemicals in the root extract may be responsible for the observed effects, and also the basis for its use in traditional medicine as antidiarrhoeal drug. Key words: Azima tetracantha, enteropooling, anti-diarrhoeal. INTRODUCTION Diarrhoea is characterized by increased frequency of powerful diuretic given in rheumatism, dropsy, dyspepsia bowel movement, wet stool and abdominal pain and chronic diarrhoea and as a stimulant tonic after (Ezekwesili et al., 2004). It is a leading cause of confinement (Nadkarni, 1976). A. tetracantha as efficient malnutrition and death among children in the developing acute phase anti-inflammatory drug is traditionally used countries of the world today (Victoria et al., 2000). Many by Indian medical practitioners (Ismail et al., 1997).